Vitamin B3 for Alzheimer's in Down syndrome
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial is testing whether a form of vitamin B3 (called NAD) can help prevent or slow down Alzheimer's disease in people with Down syndrome. The goal is to see if this supplement can protect brain cells and improve memory or thinking.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older.
- Have a confirmed diagnosis of Down syndrome (full trisomy 21 or complete translocation of chromosome 21).
- Have a caregiver or family member who spends at least 10 hours per week with you and can provide information about your health.
- Not be pregnant or planning to become pregnant for the next 6 months.
- Have generally stable health (no recent heart attack, stroke, or serious illness in the past 3 months, no active substance use or untreated mental health conditions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a drug called donanemab can lower amyloid plaques in the brains of adults with Down syndrome who are at risk for Alzheimer's disease. The goal is to see if it can slow or prevent memory and thinking problems.
This trial tests whether taking creatine and HMB supplements can improve muscle strength, reduce inflammation, and increase muscle mass in people with Down syndrome. It may help if you or your loved one can do basic physical tests like standing from a chair and do not have kidney disease or severe mobility issues.
This study tests whether a drug called memantine can help people with Down syndrome. It aims to see if it's safe and if it improves memory or thinking.
This study tests whether a daily supplement (nicotinamide riboside, a form of vitamin B3) can slow the progression of early Alzheimer's disease over two years. It is a randomized, double-blind trial, meaning half the participants will get the supplement and half will get a placebo (a pill with no active ingredient), and neither you nor the doctors will know which you are getting.
This trial tests a new drug called mivelsiran designed to slow early-stage Alzheimer's disease in adults with Down syndrome. The drug works by targeting amyloid, a protein that builds up in the brain and causes cognitive decline.
This study tests if nicotinic acid (a form of vitamin B3) can help people with mild to moderate Alzheimer's disease. It involves taking a daily pill, having a lumbar puncture, and regular check-ups to see if the vitamin improves thinking and memory.
Hear when a new Down Syndrome (DS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.